Skip to Main Content

Paper Details

A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
Clin Cancer Res
65
2018
-ketogluterate, -ketogluterate dehydrogenase, AML, AML cells, B cells, CPI-613, Cytarabine, KGDH, Mitoxantrone, PDH, Relapsed or Refractory Acute Myeloid Leukemia, acute myeloid leukemia, cell lines, cytarabine, lipoate, mitoxantrone, myeloid malignancies, oxygen, p53, patients, pyruvate, pyruvate dehydrogenase
Author NameAffiliation
Timothy S PardeeComprehensive Cancer Center of Wake Forest Baptist Health
Timothy S PardeeComprehensive Cancer Center of Wake Forest Baptist Health
Timothy S PardeeRafael Pharmaceuticals Inc
Lance D MillerComprehensive Cancer Center of Wake Forest Baptist Health
Jeff W Chou
Jeff W ChouComprehensive Cancer Center of Wake Forest Baptist Health
  • 1 - 6

Datasets

Release 1.2